Steroid-resistant inflammation in a mouse model of severe asthma is not inhibited by the combination of theophylline and budesonide Source: International Congress 2018 – Basic pharmacology Year: 2018
Inhaled PPAR-r agonist inhibit the airway inflammation in murine model of acute and chronic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 24s Year: 2007
CTLA4-Ig enhanced glucocorticoid effect on murine asthma Source: International Congress 2017 – Animal models of asthma and allergies Year: 2017
A fully dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a murine model of asthma Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010
Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
Pharmacological characterization of the protective effect of benralizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
Decreased Smad7 expression in the airways of a mouse model of chronic asthma Source: Annual Congress 2004 - Animal models of allergic airway disease Year: 2004
Formoterol restores corticosteroid responses in corticosteroid-insensitive severe asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
MMP-9 deficiency reduces airway inflammation and hyperresponsiveness in a mouse model of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 20s Year: 2001
Treatment with gp120 reduces AHR and airway inflammation in a humanized mouse model of asthma bronchiale Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Overexpression of eNOS suppresses asthmatic features in a mouse model of allergic asthma Source: Eur Respir J 2002; 20: Suppl. 38, 28s Year: 2002
PDE-4-inhibitor rolipram supports treg-mediated suppression in a murine model of allergic airway disease Source: Annual Congress 2008 - Risk factors for asthma versus asthma control Year: 2008
EP4 agonist increases myeloid derived suppressor cells activity and reduces airway inflammatory events in a murine model of asthma Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020
Dose-dependent effects of muIL-13Rα2, a potent IL-13 neutraliser, on the phenotype of an acute allergic airways inflammation model in BALB/c mice Source: Annual Congress 2004 - Animal models of asthma and chronic bronchitis and their relevance in pulmonary pharmacology Year: 2004
The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Targeting PI3Kd attenuates influenza virus-induced inflammation in a murine model of asthma exacerbation Source: International Congress 2017 – Infection and exacerbation science Year: 2017
Photobiomodulation and corticosteroid modulate pulmonary inflammation and airway reactivity in an experimental model of chronic asthma Source: International Congress 2018 – Basic pharmacology Year: 2018
Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002
Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005
Influence of CpG-oligodeoxynucleotides and dexamethasone on remodeling and expression of MMP-9 in murine model of chronic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 224s Year: 2006